Literature DB >> 8930779

Influence of food on the oral bioavailability of loratadine and pseudoephedrine from extended-release tablets in healthy volunteers.

A A Nomeir1, P Mojaverian, T Kosoglou, M B Affrime, J Nezamis, E Rodwanski, C C Lin, M N Cayen.   

Abstract

The effect of a high-fat breakfast on the bioavailability of the components of an extended-release tablet containing 10 mg loratadine in the immediate-release coating and 240 mg pseudoephedrine sulfate in the extended-release core was studied in 24 healthy male volunteers in a single-dose, two-way crossover study. The drug was administered after a 10-hour overnight fast or within 5 minutes of consuming a standardized high-fat breakfast. Serial blood samples were collected over a 48-hour period, and plasma was analyzed for loratadine and its active metabolite descarboethoxyloratadine (DCL), and pseudoephedrine. For pseudoephedrine, maximum concentration (Cmax) and area under the concentration-time curve extrapolated to infinity (AUCzero-infinity) were similar after both treatments, indicating no relevant food effect on the bioavailability of pseudoephedrine. Also, the absorption profiles of pseudoephedrine (from Wagner-Nelson analysis) were similar for the fed and fasted treatments, indicating no apparent differences in absorption. Plasma concentration-time profiles and values for Cmax and AUCzero-infinity of DCL were similar for the two treatments, indicating no relevant food effect on the pharmacokinetics of DCL. In contrast, for loratadine, administration with food resulted in a significantly increased mean Cmax (53%) and AUC from time zero to the final quantifiable sample (AUCif) (76%). However, the resultant Cmax and AUC of loratadine under fed conditions were well below those previously obtained at steady-state after multiple-dose administration of loratadine (40 mg/day) that were shown to be safe and well-tolerated in several clinical studies. The effect of food on the bioavailability and pharmacokinetic profiles of the components of a combination loratadine/pseudoephedrine extended-release tablet is not likely to be clinically significant.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8930779     DOI: 10.1002/j.1552-4604.1996.tb04759.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  7 in total

1.  Bias in the Wagner-Nelson estimate of the fraction of drug absorbed.

Authors:  Yibin Wang; Jerry Nedelman
Journal:  Pharm Res       Date:  2002-04       Impact factor: 4.200

2.  Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys.

Authors:  A A Nomeir; P Kumari; M J Hilbert; S Gupta; D Loebenberg; A Cacciapuoti; R Hare; G H Miller; C C Lin; M N Cayen
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

3.  Investigating the use of liquisolid compacts technique to minimize the influence of pH variations on loratadine release.

Authors:  Mazen El-Hammadi; Nisrine Awad
Journal:  AAPS PharmSciTech       Date:  2011-11-19       Impact factor: 3.246

Review 4.  Clinical pharmacology of new histamine H1 receptor antagonists.

Authors:  F E Simons; K J Simons
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

Review 5.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 6.  Effects of food on clinical pharmacokinetics.

Authors:  B N Singh
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

7.  Actual therapeutic management of allergic and hyperreactive nasal disorders.

Authors:  Claudia Rudack
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2004-12-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.